The co-expression of EGFR and FGFR2 linked to resistance to EGFR kinase inhibitors in esophageal cancer was reported [47], while the co-expression of EGFR and EPHA2 was found associated with the promotion of tumorigenesis in lung and colorectal cancer [53]. The gene discussed is EGFR; the disease is esophageal cancer.